Prescription Drug Affordability Board Engagement Services

A comprehensive suite of engagement and monitoring services to empower businesses in navigating the complexities of PDABs.

The landscape of prescription drug affordability is rapidly evolving. With multiple states already establishing Prescription Drug Affordability Boards (PDABs) and others following suit, staying informed about these developments is crucial for businesses in the pharmaceutical, insurance, and healthcare sectors.

PDABs play a key role in regulating drug costs. The specific duties of PDABs and similar groups may vary from state to state; however, most possess the authority to review the cost of prescription drugs, assess their affordability, set upper payment limits (UPLs), engage with drug manufacturers, and advocate for transparency in prescription drug pricing.

Navigating the complexities of PDABs can be challenging. Stateside simplifies the process with a comprehensive suite of engagement and monitoring services tailored to your specific needs.

Here's how we can help:

  • 24/7 PDAB Activity Tracking: Our team attends every PDAB meeting and monitors advisory council discussions, ensuring you never miss a beat. Receive concise meeting summaries within one business day, customized to keep you informed about relevant discussions and decisions.
  • Legislative and Regulatory Monitoring: We stay on top of all legislative proposals and regulatory developments related to PDABs, including new board creation, existing board amendments, upper payment limit regulations, and cost review processes. Timely email updates keep you informed about committee activities, votes, and rulemaking publications
  • Monthly Reports: Stay ahead of potential challenges and opportunities with our monthly reports, including meeting summaries, board recommendations, proposed rules, upcoming meeting information, and details on board members and advisory councils.
  • Accessibility and Confidentiality: We are your dedicated resource for all things PDAB-related. Our team is readily available to answer your questions and clarify any uncertainties you may have about PDAB policies, activity, or expectations.

Elevate your engagement:

  • Bi-Weekly Calls: Gain deeper insights and discuss evolving strategies through bi-weekly calls with our dedicated team. These calls offer a platform for open dialogue and collaboration to ensure you remain proactive in the PDAB landscape.
  • Direct Engagement Support: We assist you in crafting impactful comment letters, testimonies, and presentations, ensuring compliance with board processes and maximizing your influence. Additionally, we help you navigate the application process for stakeholder and advisory council vacancies, expanding your engagement opportunities.
  • Customized Analysis: We can analyze a variety of Board-related materials, including information submitted by manufacturers for previous affordability reviews, Board member voting patterns and frequent topics of discussion, as well as priority data points that are heavily relied upon during the selection and review process. This analysis is customized to help you build a stronger, more tailored engagement strategy with each Board at every step of the process.

Ready to gain a competitive edge with comprehensive PDAB expertise? Contact us today to request a sample report or discuss how our services can benefit your organization.


Zach Cook_Stateside Associates

Zachary Cook
Senior Director & Counsel, Health Care Policy

phone: (703) 525-7466 ext. 247

Current Updates with Prescription Drug Affordability Boards (PDABs)
States with an Authorized PDAB States with Active Legislation to Create PDABs States Discussing PDABs
Colorado Illinois Arizona
Maine Massachusetts Connecticut
Maryland Michigan Iowa
Minnesota New Jersey** Kentucky
New Hampshire New York Nebraska
New Jersey* Pennsylvania Rhode Island
Oregon South Carolina
Washington Virginia
Vermont*** West Virginia

Data as of June 25, 2024

*New Jersey has created a Drug Affordability Council, which has the authority to recommend affordability strategies.
**New Jersey has proposed the creation of the Prescription Drug and Biological Product Review Commission, which would have the authority to set upper payment limits
***SB 98 directed the Green Mountain Care Board to study existing PDABs and develop a prescription drug price control program.


Request a Sample Report Below